Adipocytokines and breast cancer risk

Hou, Wei-Kai; Xu, Yuxin; Yu, Ting; Zhang, Li; Zhang, Wen; Fu, Chunli; Sun, Yu; Wu, Qing; Chen, Li

doi:10.1097/00029330-200709020-00009

Cited by 126 publications

(79 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reviewing the literature, it is clear that little is known about the resistin-breast cancer link. Two small casecontrol studies found that plasma levels of resistin were elevated among patients with breast cancer as compared with controls [31,32], which is consistent with the current study results. Of note, the observations made among control subjects in this study revealed that plasma resistin was not correlated with anthropometric measures of adiposity (Fig.…”

Section: Discussionsupporting

confidence: 92%

Adipocytokine resistin and breast cancer risk

Sun

Chu

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Adipocytokine resistin is a member of the newly discovered family of cysteine-rich protein. Recent data suggest that macrophages are a major source of human resistin. Given the obesity-breast cancer link and convergence of adipocyte and macrophage function, resistin may provide unique insight into links between obesity, inflammation, and breast cancer risk in humans. We conducted a hospital-based case-control study to evaluate whether plasma resistin levels were associated with breast cancer risk in women. We also examined the modification effect of estrogen exposures on the resistin-breast cancer link. Questionnaire information, anthropometric measures, and blood samples were taken before treatment from 380 incident cases with breast cancer and 760 controls admitted for health examination at the Tri-Service General Hospital, Taipei between 2004 and 2008. Plasma levels of resistin were measured by enzyme immunoassay. Cumulative exposure to estrogens were estimated according to the age at menarche and age at enrollment for premenopausal women and age at menarche and age at menopause for postmenopausal women. Cases with breast cancer had significantly elevated resistin concentrations as compared with control subjects. Compared with those in the lowest quartile, the adjusted odds ratios of breast cancer for women in the second, third, and highest quartiles were 1.48 [95% confidence interval (CI) = 0.65-3.38], 1.76 (95% CI = 1.00-4.73), and 2.08 (95% CI = 1.04-3.85), respectively. Furthermore, the biological gradient of breast cancer risk by plasma resistin levels remained after adjustment for measures of adiposity. The dose-dependent relationship of resistin levels with breast cancer risk was notably pronounced among women with excess exposure to estrogens. Adipocytokine resistin may have an adiposity-independent role in breast carcinogenesis. Mechanistic studies to fully elucidate the mechanisms underlying resistin's effects should be pursued in future investigations.

show abstract

Section: Discussionsupporting

confidence: 92%

Adipocytokine resistin and breast cancer risk

Sun

Chu

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…This finding was supported by both Chen et al [16] and Kang et al [19]. However, other groups reported that low adiponectin levels are associated with breast cancer only in post-menopausal women [15,17,20,22]. The effect of female hormones on adiponectin might help resolve this divergence since serum adiponectin concentration has a significant negative correlation with serum estradiol concentration in post-menopausal but not in pre-and peri-menopausal women [24].…”

Section: Low Adiponectin Levels and Breast Cancer Riskmentioning

confidence: 72%

“…Miyoshi et al was the first to report that low serum adiponectin levels are significantly associated with increased risk of breast cancer [14]. This potential link was confirmed by several subsequent retrospective case-control observations [15][16][17][18][19][20]. HMW was also shown to be strongly and inversely associated with breast cancer risk, though this relationship does not offer additional predictive value [21].…”

Section: Low Adiponectin Levels and Breast Cancer Riskmentioning

confidence: 97%

Adiponectin and breast cancer

Chen¹,

Wang²

2010

Med Oncol

View full text Add to dashboard Cite

Adiponectin, an adipose tissue-derived hormone, has been studied intensively for the past decade because of its anti-inflammatory, anti-atherogenic, and anti-diabetic properties. Recent advances suggest that adiponectin also plays an important role in the development and progression of various cancers, especially obesity-related cancers. In this review, the authors focus on the potential role of adiponectin in breast cancer, an obesity- and endocrine-associated tumor. Epidemiological studies have shown that plasma adiponectin level is a risk factor for breast cancer in post-menopausal women. Adiponectin and its receptors are expressed on both breast cancer line cells and tumor tissues. Furthermore, exogenous adiponectin has exhibited therapeutic potential in animal models. Underlying mechanisms include the inhibition of cell proliferation and promotion of apoptosis, the regulation of tumorigenic-related factors, and the suppression of angiogenesis. The signaling pathways linking adiponectin with tumorigenesis might provide potential drug targets for the future. However, more convincing evidence is needed to fully elucidate the exact role of adiponectin in breast cancer, since both its beneficial effects and possible mechanisms remain controversial.

show abstract

“…However, an interesting finding was that the serum leptin to adiponectin ratio increased significantly in breast cancer patients as compared with controls; and this ratio had a positive and significant correlation with tumor size. In another study, Hou et al [95] analyzed blood samples of 80 breast cancer patients (43 premenopausal and 37 postmenopausal) and 50 healthy women (26 premenopausal and 24 postmenopausal). They found that serum adiponectin levels were significantly lower whereas serum levels of leptin were significantly higher in postmenopausal breast cancer patients compared to controls.…”

Section: Studies On Breast Cancer Which Considered Both Leptin and Admentioning

confidence: 99%

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

Großmann

Ray

Nkhata

et al. 2010

Cancer Metastasis Rev

161

108

View full text Add to dashboard Cite

It is well recognized that obesity increases the risk of various cancers, including breast malignancies in postmenopausal women. Furthermore, obesity may adversely affect tumor progression, metastasis, and overall prognosis in both pre- and postmenopausal women with breast cancer. However, the precise mechanism(s) through which obesity acts is/are still elusive and this relationship has been the subject of much investigation and speculation. Recently, adipose tissue and its associated cytokine-like proteins, adipokines, particularly leptin and adiponectin, have been investigated as mediators for the association of obesity with breast cancer. Higher circulating levels of leptin found in obese subjects could be a growth-enhancing factor as supported by in vitro and preclinical studies, whereas low adiponectin levels in obese women may be permissive for leptin's growth-promoting effects. These speculations are supported by in vitro studies which indicate that leptin promotes human breast cancer cell proliferation while adiponectin exhibits anti-proliferative actions. Further, estrogen and its receptors have a definite impact on the response of human breast cancer cell lines to leptin and adiponectin. More in-depth studies are needed to provide additional and precise links between the in vivo development of breast cancer and the balance of adiponectin and leptin.

show abstract

Adipocytokines and breast cancer risk

Cited by 126 publications

References 15 publications

Adipocytokine resistin and breast cancer risk

Adipocytokine resistin and breast cancer risk

Adiponectin and breast cancer

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

Contact Info

Product

Resources

About